
Biomarker identifies high-risk COVID-19 patients
The findings of virologists headed by Elisabeth Puchhammer-Stöckl from the Medical University Vienna may pave the way to early identification of...

Cellectis and Cytovia in US$760m licence deal
Cytovia Therapeutics, Inc. and French Cellectis SAS have struck a licence deal to combine their different expertises in allogenic cancer cell...

Two companies aim for 2nd-gen COVID vaccines
As scientific papers provide hints that mutants of SARS-CoV-2 that carry the N501Y and E484K mutations are able to reproduce more rapidly as the...

Oxular Ltd raises US$37m
Oxford-based Oxular said it will use the proceeds to finance Phase II studies evaluatingO the company’s lead asset, OXU-001, for the treatment of...

Abingworth raises US-$465m for new life sciences fund
UK-US venture capitalist Abingworth yesterday announced the final closing of its 13th life sciences venture fund, ABV 8, at US$465m exceeding...

EU orders additional COVID-19 vaccine doses
Under the new deal, the Commission has the option to request supply of an additional 100 million doses. This new agreement is in addition to the 300...

PCR-test reveals risk of genotoxity of genome editing
The new method called single targeted linker-mediated PCR sequencing (CAST-Seq), developed at University Hospital Freiburg, Germany, is set to become...